{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:19:27Z","timestamp":1791919167996,"version":"4.3.4"},"reference-count":28,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Medical University of Silesia","award":["BNW-2-055\/N\/3\/I"],"award-info":[{"award-number":["BNW-2-055\/N\/3\/I"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn\u2019s disease (CD), is a chronic inflammatory disorder driven by a complex interplay of immune and proteolytic mechanisms. Neutrophil elastase (NE), released at sites of inflammation, plays a central role by promoting inflammation, degrading the extracellular matrix (ECM), and disturbing intestinal barrier integrity via NF-\u03baB activation and E-cadherin degradation. Elafin, an endogenous NE inhibitor, mitigates proteolytic damage, reinforces the intestinal barrier, and exerts anti-inflammatory effects by suppressing NF-\u03baB and reducing pro-inflammatory cytokines. Since the NE\/elafin balance is critical in IBD, assessing their ratio may provide a more precise measure of proteolytic dysregulation. This study aimed to evaluate the diagnostic and prognostic utility of urinary NE, elafin, and their ratio in IBD patients. Methods: Urinary concentrations of NE and elafin were measured by immunoassay in 88 subjects including ulcerative colitis and Crohn\u2019s disease patients and healthy individuals. The diagnostic accuracy of these biomarkers was assessed using receiver operating characteristic (ROC) curve analysis. Results: Urinary NE levels were significantly elevated in both UC and CD patients compared to controls, with a 17-fold increase in the UC patients and a 28-fold increase in the CD patients (p &lt; 0.0001). Elafin levels were also increased in IBD patients. The NE\/elafin ratio was significantly increased in both disease groups, with a 4.5-fold increase in the UC and 5.6-fold increase in the CD patients compared to healthy controls. The ROC curve analysis demonstrated that the NE\/elafin ratio is the most effective biomarker for distinguishing CD patients from healthy individuals (AUC = 0.896), with a high sensitivity (92.9%) and specificity (69.7%), making it a strong diagnostic tool. NE also showed an excellent diagnostic performance both in CD (AUC = 0.842) and UC (AUC = 0.880). The elafin urinary profile had a high diagnostic value, with a better accuracy in the UC patients (AUC = 0.772) than the CD patients (AUC = 0.674), though it was inferior to NE and NE\/elafin. Conclusions: Our findings indicate that urinary NE, elafin, the and NE\/elafin ratio have significant diagnostic value in differentiating IBD patients from healthy controls. The NE\/elafin ratio and NE proved to be the most reliable urinary biomarkers in both CD and UC diagnosis, with a high predictive value and strong discriminatory power.<\/jats:p>","DOI":"10.3390\/jcm14072466","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T06:52:56Z","timestamp":1743749576000},"page":"2466","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Neutrophil Elastase and Elafin in Inflammatory Bowel Diseases: Urinary Biomarkers Reflecting Intestinal Barrier Dysfunction and Proteolytic Activity"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9818-9221","authenticated-orcid":false,"given":"Aleksandra","family":"G\u00f3recka","sequence":"first","affiliation":[{"name":"Department of Clinical Chemistry and Laboratory Diagnostics, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in Katowice, 41-200 Sosnowiec, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2307-5884","authenticated-orcid":false,"given":"Katarzyna","family":"Komosinska-Vassev","sequence":"additional","affiliation":[{"name":"Department of Clinical Chemistry and Laboratory Diagnostics, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in Katowice, 41-200 Sosnowiec, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41572-020-0205-x","article-title":"Ulcerative colitis","volume":"6","author":"Kobayashi","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.gtc.2020.07.001","article-title":"Ulcerative Colitis: Making the Diagnosis","volume":"49","author":"Kaenkumchorn","year":"2020","journal-title":"Gastroenterol. Clin. N. Am."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s11894-019-0705-6","article-title":"Evolving Epidemiology of IBD","volume":"21","author":"Windsor","year":"2019","journal-title":"Curr. Gastroenterol. Rep."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.cca.2020.08.025","article-title":"Calprotectin in inflammatory bowel disease","volume":"510","author":"Qujeq","year":"2020","journal-title":"Clin. Chim. Acta"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1053\/j.gastro.2020.03.007","article-title":"Serum biomarkers identify patients who will develop inflammatory bowel diseases up to 5 years before diagnosis","volume":"159","author":"Torres","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1093\/ibd\/izab228","article-title":"Early Diagnosis, Early Stratification, and Early Intervention to Deliver Precision Medicine in IBD","volume":"28","author":"Noor","year":"2022","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_7","first-page":"155","article-title":"Biomarkers in inflammatory bowel diseases: Insight into diagnosis, prognosis and treatment","volume":"10","author":"Norouzinia","year":"2017","journal-title":"Gastroenterol. Hepatol. Bed Bench"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jpha.2022.12.003","article-title":"Neutrophil elastase: From mechanisms to therapeutic potential","volume":"13","author":"Zeng","year":"2023","journal-title":"J. Pharm. Anal."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/s41385-019-0235-4","article-title":"Faecal neutrophil elastase-antiprotease balance reflects colitis severity","volume":"13","author":"Barry","year":"2020","journal-title":"Mucosal Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"8243378","DOI":"10.1155\/2021\/8243378","article-title":"Interplay between Extracellular Matrix and Neutrophils in Diseases","volume":"2021","author":"Zhu","year":"2021","journal-title":"J. Immunol. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"105779","DOI":"10.1016\/j.phrs.2021.105779","article-title":"Neutrophil extracellular traps in inflammatory bowel diseases: Implications in pathogenesis and therapeutic targets","volume":"171","author":"Viana","year":"2021","journal-title":"Pharmacol. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.biochi.2007.09.007","article-title":"Multifaceted roles of human elafin and secretory leukocyte proteinase inhibitor (SLPI), two serine protease inhibitors of the chelonianin family","volume":"90","author":"Moreau","year":"2008","journal-title":"Biochimie"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/bph.15985","article-title":"Elafin and its precursor trappin-2: What is their therapeutic potential for intestinal diseases?","volume":"180","author":"Deraison","year":"2023","journal-title":"Br. J. Pharmacol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e678","DOI":"10.1016\/j.crohns.2013.06.008","article-title":"Serum calprotectin as a biomarker for Crohn\u2019s disease","volume":"7","author":"Meuwis","year":"2013","journal-title":"J. Crohns Colitis"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/BF03326409","article-title":"Possible involvement of neutrophil elastase in impaired mucosal repair in patients with ulcerative colitis","volume":"37","author":"Kuno","year":"2002","journal-title":"J. Gastroenterol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2147\/JIR.S234710","article-title":"Human Neutrophil Elastase Proteolytic Activity in Ulcerative Colitis Favors the Loss of Function of Therapeutic Monoclonal Antibodies","volume":"13","author":"Curciarello","year":"2020","journal-title":"J. Inflamm. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"G705","DOI":"10.1152\/ajpgi.2001.281.3.G705","article-title":"Neutrophil-mediated epithelial injury during transmigration: Role of elastase","volume":"281","author":"Ginzberg","year":"2001","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s12672-024-01010-3","article-title":"Targeting neutrophil elastase is a promising direction for future cancer treatment","volume":"15","author":"Jia","year":"2024","journal-title":"Discov. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1572-0241.2007.01556.x","article-title":"Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: Performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices","volume":"103","author":"Langhorst","year":"2008","journal-title":"Am. J. Gastroenterol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Wang, J., Ortiz, C., Fontenot, L., Xie, Y., Ho, W., Mattai, S.A., Shih, D.Q., and Koon, H.W. (2020). High circulating elafin levels are associated with Crohn\u2019s disease-associated intestinal strictures. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0231796"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Krawiec, P., and Pac-Ko\u017cuchowska, E. (2022). Clinical Significance of Serum Elafin in Children with Inflammatory Bowel Disease. Biomedicines, 10.","DOI":"10.3390\/biomedicines10123267"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1189\/jlb.0906581","article-title":"Attenuated induction of epithelial and leukocyte serine antiproteases elafin and secretory leukocyte protease inhibitor in Crohn\u2019s disease","volume":"81","author":"Schmid","year":"2007","journal-title":"J. Leukoc. Biol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.biocel.2012.05.007","article-title":"The WAP protein Trappin-2\/Elafin: A handyman in the regulation of inflammatory and immune responses","volume":"44","author":"Verrier","year":"2012","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5534","DOI":"10.3390\/cimb45070350","article-title":"Inflammation, Autoinflammation and Autoimmunity in Inflammatory Bowel Diseases","volume":"45","author":"Padoan","year":"2023","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1053\/j.gastro.2010.12.050","article-title":"Modifying the protease, antiprotease pattern by elafin overexpression protects mice from colitis","volume":"140","author":"Motta","year":"2011","journal-title":"Gastroenterology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1042\/BST0391450","article-title":"Therapeutic potential of human elafin","volume":"39","author":"Shaw","year":"2011","journal-title":"Biochem. Soc. Trans."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"13875","DOI":"10.1074\/jbc.M115.642736","article-title":"Neutrophil Elastase Activates Protease-activated Receptor-2 (PAR2) and Transient Receptor Potential Vanilloid 4 (TRPV4) to Cause Inflammation and Pain","volume":"290","author":"Zhao","year":"2015","journal-title":"J. Biol. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Hanning, N., De Bruyn, M., Ceuleers, H., Boogaerts, T., Berg, M., Smet, A., De Schepper, H.U., Joossens, J., van Nuijs, A.L.N., and De Man, J.G. (2021). Local Colonic Administration of a Serine Protease Inhibitor Improves Post-Inflammatory Visceral Hypersensitivity in Rats. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13060811"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/7\/2466\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:10:06Z","timestamp":1760029806000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/7\/2466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,4]]},"references-count":28,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["jcm14072466"],"URL":"https:\/\/doi.org\/10.3390\/jcm14072466","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,4]]}}}